Mainz BioMed LOGO PANTONE@4x-100.jpg
Mainz BioMed Appoints Karen Richards as Vice President, Regulatory Affairs to Lead US FDA Approval Process
December 21, 2021 03:01 ET | Mainz BioMed NV
BERKELEY, Calif. and MAINZ, Germany, Dec. 21, 2021 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the...
Mainz BioMed LOGO PANTONE@4x-100.jpg
Mainz Biomed Expands ColoAlert Commercialization with GANZIMMUN Diagnostics in Europe
December 14, 2021 03:01 ET | Mainz BioMed NV
Mainz to co-brand ColoAlert with GANZIMMUN Diagnostics, one of the largest stool analysis labs in GermanyGANZIMMUN Diagnostics has an interdisciplinary team of over 370 medical technical assistants,...
Mainz BioMed LOGO PANTONE@4x-100.jpg
Mainz Biomed Launches Ecommerce Store for ColoAlert to Assist Patient Access during Covid-19 Pandemic
December 07, 2021 03:01 ET | Mainz BioMed NV
BERKELEY, Calif. and MAINZ, Germany, Dec. 07, 2021 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the...
Mainz BioMed LOGO PANTONE@4x-100.jpg
Mainz Biomed Establishes Partnership with Precision for Medicine to Support ColoAlert’s U.S. Regulatory and Commercial Strategy
November 30, 2021 03:01 ET | Mainz BioMed NV
BERKELEY, Calif. and MAINZ, Germany, Nov. 30, 2021 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostics company specializing in the...
Mainz BioMed LOGO PANTONE@4x-100.jpg
Mainz Biomed Appoints Dr. Soren Thestrup-Nielsen M.D. to Strategic Advisory Board
November 18, 2021 03:01 ET | Mainz BioMed NV
Former Danaher executive provides significant clinical, global market, and product development expertise in cancer diagnostics BERKELEY, Calif. and MAINZ, Germany, Nov. 18, 2021 (GLOBE NEWSWIRE) --...
Mainz BioMed LOGO PANTONE@4x-100.jpg
Mainz Biomed to Exhibit ColoAlert at MEDICA 2021, the World’s Largest Medical Trade Fair
November 15, 2021 03:01 ET | Mainz BioMed NV
BERKELEY, Calif. and MAINZ, Germany, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the...
Mainz BioMed LOGO PANTONE@4x-100.jpg
Mainz Biomed Appoints Former Roche Division President Heiner Dreismann to Strategic Advisory Board
November 11, 2021 03:01 ET | Mainz BioMed NV
Former President and CEO of Roche Molecular Systems and Member of Roche's Global Diagnostic Executive Committee BERKELEY, Calif. and MAINZ, Germany, Nov. 11, 2021 (GLOBE NEWSWIRE) -- Mainz...
Mainz BioMed LOGO PANTONE@4x-100.jpg
Mainz Biomed Announces Exercise of Over-Allotment Option
November 08, 2021 13:45 ET | Mainz BioMed NV
BERKELEY, Calif. and MAINZ, Germany, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the...
Mainz BioMed LOGO PANTONE@4x-100.jpg
Mainz Biomed Commences Trading on Nasdaq Under Ticker Symbol ‘MYNZ’
November 08, 2021 03:01 ET | Mainz BioMed NV
Flagship product ‘ColoAlert’ provides a unique, life-saving early detection test for colorectal cancerEuropean registration completed and commercial rollout underway across multiple territoriesFDA...
Mainz BioMed LOGO PANTONE@4x-100.jpg
MYNZ Closes Its First Day of Trading on the Nasdaq Capital Market
November 05, 2021 16:23 ET | Mainz BioMed NV
BERKELEY, Calif. and MAINZ, Germany, Nov. 05, 2021 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostics company specializing in the...